Fenofibrate 48/145 mg tabs — $0 with Membership

Related medications

Other medications associated with the same conditions in this catalog.

Also listed for Hyperlipidemia (High Cholesterol/Triglycerides)

• Atorvastatin
• Pravastatin
• Rosuvastatin
• Simvastatin

What Fenofibrate 48/145 mg tabs is approved for (FDA label)

Fenofibrate tablets are indicated as adjunctive therapy to diet: to reduce triglyceride (TG) levels in adults with severe hypertriglyceridemia (TG greater than or equal to 500 mg/dL). to reduce elevated low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia when use of recommended LDL-C lowering therapy is not possible. Limitations of Use Markedly elevated levels of serum TG (e.g. > 2,000 mg/dL) may increase the risk of developing pancreatitis.

Source: Read the full FDA label on DailyMed. Label effective date: September 9, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Fenofibrate 48/145 mg tabs (FDA label)

Fenofibrate Tablets: 48 mg: Yellow coloured, oval shaped, biconvex film coated tablets, debossed with ‘Cipla’ on one side and code ‘459’ on other side. 145 mg: White to off white coloured, oval shaped, biconvex film coated tablets, debossed with ‘Cipla’ on one side and code ‘458’ on other side. Tablets: 48 mg and 145 mg ( 3 ).

Source: FDA prescribing information (DailyMed). Set ID: c870ea48-5dde-4a6f-9ddb-56b494bb2b55. SPL document ID: d44a64dc-52e9-4cd0-b173-70c97a0d524c. Label effective date: September 9, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Fenofibrate 48/145 mg tabs (FDA label)

The following serious adverse reactions are described below and elsewhere in the labeling: Mortality and coronary heart disease morbidity [see Warnings and Precautions (5.1) ] Hepatoxicity [see Warnings and Precautions (5.2) ] Myopathy and Rhabdomyolysis [see Warnings and Precautions (5.3) ] Increases in Serum Creatinine [see Warnings and Precautions (5.4) ] Cholelithiasis [see Warnings and Precautions (5.5) ] Increased Bleeding Risk with Coumarin Anticoagulants [see Warnings and Precautions (5.6) ] Pancreatitis [see Warnings and Precautions (5.7) ] Hematologic Changes [see Warnings and Precautions (5.8) ] Hypersensitivity reactions [see Warnings and Precautions (5.9) ] Venothromboembolic disease [see Warnings and Precautions (5.10) ] Paradoxical Decreases in HDL Cholesterol Levels [see Warnings and Precautions (5.11) ] Adverse reactions (≥ 2% and greater than placebo): abnormal liver tests, increased AST, increased ALT, increased CPK, and rhinitis (6.1) . To report SUSPECTED ADVERSE REACTIONS, contact Cipla Ltd. at 1-866-604-3268 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

Source: FDA prescribing information (DailyMed). Set ID: c870ea48-5dde-4a6f-9ddb-56b494bb2b55. SPL document ID: d44a64dc-52e9-4cd0-b173-70c97a0d524c. Label effective date: September 9, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Fenofibrate 48/145 mg tabs (FDA label)

Fenofibrate is contraindicated in patients with: Severe renal impairment, including those with end-stage renal disease (ESRD) and those receiving dialysis [see Clinical Pharmacology (12.3) ]. Active liver disease, including those with unexplained persistent liver function abnormalities [see Warnings and Precautions (5.2) ]. Pre-existing gallbladder disease [see Warnings and Precautions (5.5) ]. Hypersensitivity to fenofibrate, fenofibric acid, or any of the excipients in fenofibrate tablets. Serious hypersensitivity reactions including anaphylaxis and angioedema have been reported with fenofibrate [see Warnings and Precautions (5.9) ]. Severe renal impairment, including those with end-stage renal disease (ESRD) and those receiving dialysis (4). Active liver disease including those with unexplained persistent liver function abnormalities (4). Pre-existing gallbladder disease (4). Hypersensitivity to fenofibrate, fenofibric acid, or any of the excipients in fenofibrate tablets (4) .

Source: FDA prescribing information (DailyMed). Set ID: c870ea48-5dde-4a6f-9ddb-56b494bb2b55. SPL document ID: d44a64dc-52e9-4cd0-b173-70c97a0d524c. Label effective date: September 9, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Fenofibrate 48/145 mg tabs (FDA label)

Hepatotoxicity: Serious drug-induced liver injury, including liver transplantation and death, has been reported with fenofibrates, including fenofibrate tablets. Monitor patient’s liver function, including serum ALT, AST, and total bilirubin, at baseline and periodically for the duration of therapy. Discontinue if signs or symptoms of liver injury develop or if elevated enzyme levels persist (5.2). Myopathy and Rhabdomyolysis: Have been reported in patients taking fenofibrates. Risks are increased during co-administration with a statin, in geriatric patients, and in patients with renal impairment or hypothyroidism. Discontinue fenofibrate if markedly elevated CK levels occur or if myopathy is either diagnosed or suspected. Temporarily discontinue fenofibrate in patients experiencing an acute or serious condition at high risk of developing renal failure secondary to rhabdomyolysis. Inform patients of the risk of myopathy and rhabdomyolysis when starting or increasing the fenofibrate dosage.

Source: FDA prescribing information (DailyMed). Set ID: c870ea48-5dde-4a6f-9ddb-56b494bb2b55. SPL document ID: d44a64dc-52e9-4cd0-b173-70c97a0d524c. Label effective date: September 9, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Fenofibrate 48/145 mg tabs (FDA label)

Table 2 presents clinically important drug interactions with fenofibrate. Table 2. Clinically Important Drug Interactions with fenofibrate Statins Clinical Impact: Fibrates may cause myopathy when given alone. The risk of myopathy and rhabdomyolysis is increased with concomitant use of fibrates with statins. Intervention: Consider if the benefit of using fenofibrate concomitantly with statin therapy outweighs the increased risk of myopathy and rhabdomyolysis. If concomitant use is decided, monitor patients for signs and symptoms of myopathy, particularly during initiation of therapy and during upward dosage titration of statin therapy. Colchicine Clinical Impact: Cases of myopathy and rhabdomyolysis, have been reported with concomitant use of colchicine with fenofibrates. Intervention: Consider if the benefit of using colchicine concomitantly with fenofibrate outweighs the increased risk of myopathy and rhabdomyolysis. If concomitant use is decided, monitor patients for signs and symptoms of myopathy, particularly during initiation of therapy and during upward dosage titration of colchicine.

Source: FDA prescribing information (DailyMed). Set ID: c870ea48-5dde-4a6f-9ddb-56b494bb2b55. SPL document ID: d44a64dc-52e9-4cd0-b173-70c97a0d524c. Label effective date: September 9, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.